Polaris Group, Ludwig Institute partner on cancer drug
SAN DIEGO—Polaris Group and Ludwig Institute for Cancer Research Ltd. (LICR) are collaborating to develop pegylated arginine deiminase (ADI-PEG 20), Polaris' novel cancer drug, which kills tumor cells by depleting the amino acid arginine. Under the collaboration, the two organizations will explore ADI-PEG 20's potential as a cancer therapy as well as identifying other amino acid-degrading enzymes that display anti-tumor activity. LICR and Polaris have previously studied the drug in melanoma and are currently engaged in a Phase II clinical trial of the drug in small cell lung cancer. While LICR is sponsoring the trial, both parties are sharing expenses and resources for it. Polaris has plans to initiate studies of the drug effectiveness in pancreatic cancer, prostate cancer, lymphoma, leukemia and sarcoma this year.